Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
70 participants
OBSERVATIONAL
2021-04-19
2022-06-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A New Prognostic Score Model for Pancreatic Ductal Adenocarcinoma
NCT05547074
Early Detection of Pancreatic Cancer
NCT05596435
Signature for Precise Chemosensitivity Prediction in PDAC
NCT06461598
Multimodal Deep Learning Model Predicts Pancreatic Cancer Prognosis
NCT06760234
ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma
NCT05479708
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
training cohort
30 patients undergoing resection between March 2015 and December 2016 at Chinese PLA General Hospital in Beijing, China
Resection
radical R0 resection of pancreatic adenocarcinoma
validation cohort
40 patients from The Cancer Genome Atlas (TCGA) database (https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga)
Resection
radical R0 resection of pancreatic adenocarcinoma
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Resection
radical R0 resection of pancreatic adenocarcinoma
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Availability of clinicopathologic characteristics and follow-up data
* No previous history of cancer
Exclusion Criteria
* Receipt of any neoadjuvant and/or adjuvant cancer-directed therapy
* Survival time \<3 months after resection
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Fourth Affiliated Hospital of Anhui Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lei Huang
Research PI, Research Associate
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PaC-SVM1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.